Premier online and print content, written by and for #mentalhealth care physicians and professionals. Questions? Email: [email protected].
Cranbury, NJ
Joined February 2009
- Tweets24.4K
- Following5.1K
- Followers112K
- Likes3.5K
How is schizophrenia management evolving? Attend our live national broadcast to explore real-world strategies to manage side effects, support treatment persistence, and optimize long-term functional outcomes in schizophrenia. Register Today! bit.ly/4yjLpCB
Is your adult ADHD patient covered from morning to night? Our expert panel talks treatment selection, all-day symptom control, adherence, and when to add a non-stimulant. hubs.li/Q04Bl2Hr0 #ADHD #Psychiatry
In this week's episode of "Psyched Perspectives," host @tapkidmd and guest Diego Regalado, MD, discuss immigrant mental health and the importance of cultural humility. psychiatrictimes.com/view/po…
🧠 Today is #InternationalStutteringAwarenessDay.
This year, we shared the first ever interdisciplinary consensus guidelines on stuttering.
🔗 Read them here: psychiatrictimes.com/view/in…
🤖 Made with AI
🎃 The entire October issue of Psychiatric Times is now live on our website. Read it here: psychiatrictimes.com/journal…
In our latest CME article, learn how to recognize historical and persistent barriers to the ethical use of long-acting injectable antipsychotics. psychiatrictimes.com/view/ev…
Adult ADHD is more common than many clinicians think, and symptoms often look nothing like the childhood picture. Drs. Lentzsch-Parcells, Patel, and Feld break down diagnosis, comorbidities, and burden in our new Peer Exchange. hubs.li/Q04BkZ270 #ADHD
According to a new review, ADHD medications may help improve brain fog in perimenopausal women. psychiatrictimes.com/view/ad…
🎙️ Episode 2 of The Psych Consult: Second Opinion is here!
Claire Brandon, MD, and endocrinologist Caroline Messer, MD, discuss where thyroid disease and psychiatric illness overlap.
🔗 psychiatrictimes.com/view/po…
🦠 Phase 2 signal-finding trial of bezisterim for the treatment of long COVID shows safety and symptom gains, with strongest benefits for severe fatigue, post-exertional malaise, and cognitive issues. psychiatrictimes.com/view/ne…
How is schizophrenia management evolving? Attend our live national broadcast to explore real-world strategies to manage side effects, support treatment persistence, and optimize long-term functional outcomes in schizophrenia. Register Today! bit.ly/4yjLpCB
🏃 Athletes can feel the relief a substance gives them long before they can see what it costs.
Check out this composite case of cannabis use in a track athlete to learn more about how to assess. psychiatrictimes.com/view/re…
A psychiatric nurse practitioner shares mentorship lessons, training fixes, and practical tips to close prescriber gaps and improve team-based care in this week's episode of "Psyched Perspectives."
psychiatrictimes.com/view/po…
Today marks the first-ever Treatment-Resistant Depression Awareness Day in the US. psychiatrictimes.com/view/th…
Routine symptom measures can sharpen psychiatric diagnosis.
Learn how to gather consistent, evidence-based measurements from the initial evaluation and throughout patient treatment from John Rush, MD, in our October cover: psychiatrictimes.com/view/me…
Mental health care changes lives—and so do the clinicians behind it. 💚🌍
On #WorldMentalHealthDay, we’re reminded that progress in psychiatry means progress for every patient, family, and community. #MentalHealthAwareness #MentalHealth
🚨 The FDA has approved olanzapine (Weltruza) extended-release injectable suspension, a once-monthly subcutaneous long-acting injectable, for adults with schizophrenia. psychiatrictimes.com/view/ol…
Check out the latest episode of "Psychopharm Today"! This month, host Jessica Gannon, MD, interviews Andrew A. Nierenberg, MD, about how a learning health network can transform bipolar disorder care.
Watch it here: psychiatrictimes.com/view/ho…
Listen here: psychiatrictimes.com/view/po…
The October issue of Psychiatric Times is now live! This month, we're rethinking treatment resistance and measurement-based care.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6…
The FDA has cleared Motivista, a prescription digital therapeutic indicated for the negative symptoms of schizophrenia, as an adjunct to outpatient care. This is the first authorized treatment for negative symptoms of schizophrenia in the United States. psychiatrictimes.com/view/fd…
